Phase 2 N=58 GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
Melanoma · Brain Metastases
Primary: 1-year Survival Rate — 31.8 Percentage of patients alive at 1 year
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=65 MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Melanoma · Non-Small Cell Lung Cancer · Brain Metastases
Primary: Overall Response in the Brain by mRECIST — 17; 31; 6; 11 participants
Phase 1 N=25 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Metastatic Malignant Neoplasm in the Brain · Metastatic Melanoma · Mucosal Melanoma
Primary: Dose Limiting Toxicities — 0; 0; 0 Participants
Phase 2 N=41 Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Melanoma · Non-small Cell Lung Cancer · Brain Metastasis
Primary: Brain Metastasis Response Rate (BMRR) — 54.1; 75 percentage of participants
Phase 2 N=146 A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
Malignant Melanoma
Primary: Best Overall Response Rate (BORR) Within Brain of Previously Untreated Participants (Assessed by Independent Review Committee [IRC] Using Modified Response Evaluation…
Phase 2 N=48 Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Metastatic Melanoma · Brain Metastases
Primary: Intracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset — 34; 13; 1; 20 Participants
Phase 2 N=119 An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
Melanoma
Primary: Intracranial Clinical Benefit Rate (CBR) — 57.4; 16.7 Percentage of Participants
Phase 2 N=72 Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
Melanoma
Primary: Disease Control Rate by Modified World Health Organization (mWHO) Tumor Assessment Criteria — 17.6; 4.8; 23.5; 9.5 Percentage of participants
Phase 2 N=24 A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
Malignant Melanoma
Primary: Percentage of Participants With Adverse Events (AEs) — 96; 83; 92; 17 percentage of participants
Phase 2 N=8 Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
Kidney Cancer · Melanoma (Skin) · Metastatic Cancer
Primary: Central Nervous System (CNS) Response Rate by RECIST Criteria — 3; 2 participants
Phase 2 N=64 Ipilimumab + Temozolomide in Metastatic Melanoma
Metastatic Melanoma
Primary: 6-Month Progression-Free Survival (PFS) Rate — 29 participants
Phase 1 N=17 Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Recurrent Melanoma · Stage IV Melanoma · Tumors Metastatic to Brain
Primary: Maximum Tolerated Dose (MTD) of Ipilimumab — 3; 10 mg/kg
Phase 2 N=52 Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Phase 2 N=2 Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
Melanoma
Primary: Activity of Vemurafenib in Untreated Brain Metastases
Phase 2 N=172 A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
Melanoma and Brain Metastases
Primary: Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator — 4; 1; 26; 23 participants…
Phase 2 N=8 Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Liver Metastases · Lung Metastases · Recurrent Melanoma
Primary: Rate of Progression-free Survival by mWHO Criteria — 0.75 months
Phase 2 N=17 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Brain Tumor · Brain Metastases
Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 2 N=125 Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Melanoma and Brain Metastases
Primary: Intracranial Response (IR) Rate in Cohort A — 45 Number of participants — p=<.0001
Phase 2 N=18 Ipilimumab and Nivolumab in Leptomeningeal Metastases
Leptomeningeal Carcinomatosis
Primary: Percentage of Participants With Overall Survival — 44 percentage of participants
Phase 2 N=24 Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
Clinical Stage IV Cutaneous Melanoma AJCC v8 · Metastatic Malignant Neoplasm in the Brain · Metastatic Melanoma
Primary: Clinical Benefit Rate (CBR) in PD-1 naïve Patients — 68.4 percentage of participants
Phase 2 N=26 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Lung Cancer · Metastatic Cancer
Primary: Number of Patients With Intracranial Response — 3 participants
Phase 2 N=17 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Phase 2 N=4 Radiation and Combination Immunotherapy for Melanoma
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Phase 2 N=39 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
N/A N=22 Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
Phase 2 N=15 Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Phase 2 N=23 An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
Melanoma
Primary: Overall Response Rate (ORR) — 10 Percentage of Participants
Phase 2 N=4 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants
Phase 2 N=95 Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Melanoma (Skin)
Primary: Progression-free Survival at 6 Months — 32.8; 56.1 % of patients alive and progression free